Effect of Tumor Location on the Risk of Bilateral Central Lymph Node Metastasis in Unilateral 1–4 cm Papillary Thyroid Carcinoma

Nan Liu
Bo Chen
Luchuan Li
Qingdong Zeng
Lei Sheng
Bin Zhang
Bin Lv

Department of Thyroid Surgery, General Surgery, Qilu Hospital of Shandong University, Jinan, 250012, Shandong, People’s Republic of China

Purpose: Papillary thyroid carcinoma (PTC) has a high incidence of lymph node metastasis (LNM). Our aim was to determine whether tumor location is a useful feature to predict bilateral central lymph node metastasis (CLNM) in unilateral 1–4 cm PTC.

Patients and Methods: Data on unilateral 1–4 cm PTC patients from 2016 to 2019 were collected retrospectively. The clinical and pathological characteristics of the tumors and lymph nodes were analyzed statistically.

Results: The mean patient age was 49.1±12.3 (23–73) years, and the majority were women (n=1334, 75.4%). A total of 1767 patients were analyzed, and 256 (14.5%) had bilateral CLNM. Tumor location was an independent risk factor in predicting bilateral CLNM (p<0.001). The odds of bilateral CLNM were the highest in the near isthmus (OR 6.452, 95% CI: 3.658–11.379, p<0.001). In a multivariate regression model adjusting for other risk factors, near-isthmus tumors had the highest risk of bilateral CLNM (OR 7.319, 95% CI: 3.844–13.933, p<0.001), followed by lower lobe tumors (OR 2.338, 95% CI: 1.315–4.155, p=0.004) and middle lobe tumors (OR 1.845, 95% CI: 1.035–3.291, p=0.038), compared to upper lobe tumors.

Conclusion: Tumor location is an independent risk factor in predicting the risk of bilateral CLNM. Near-isthmus tumors carry the highest risk of bilateral CLNM.

Keywords: papillary thyroid carcinoma, location, predictive factor, lymph node metastasis

Introduction

Papillary thyroid carcinoma (PTC) is the most common pathological type of thyroid cancer, and the incidence of PTC has dramatically increased in recent decades.1–3 The central neck compartment is the most common site of lymph node metastasis (LNM), and PTC patients have a high incidence.4–6 The central neck compartment includes the bilateral paratracheal regions, the prelaryngeal region and the pretracheal region. A total of 40–60% of PTCs have central lymph node metastasis (CLNM), and bilateral CLNM was even found in 8.1–36.6% of unilateral PTCs.7–14 Previous studies have found that LNM can influence local recurrence and distant metastasis.15–18 However, central compartment neck dissection (CCND) can increase the risk of postoperative hypocalcemia. In terms of unilateral PTC, bilateral CCND should only be performed in patients with a high risk of bilateral CLNM.

To date, risk factors for bilateral CLNM include male sex, >1 cm PTC, extra-thyroidal extension, lateral neck LNM, and ipsilateral CLNM.8,11–14,19,20 However, little attention has been given to the effect of tumor location on the risk of bilateral...
CLNM. Therefore, we conducted this study to test the risk of bilateral CLNM based on tumor location in unilateral PTC in order to provide valuable screening criteria for thyroid surgeons.

**Patients and Methods**

**Patient Selection**

This retrospective study collected data on patients proven to have unilateral PTC by preoperative high-resolution ultrasound and fine needle aspiration at Qilu Hospital of Shandong University between January 2016 and March 2019. Only patients with 1–4 cm PTC were selected because <1 cm PTC has a low risk of bilateral CLNM, and it is difficult to pinpoint the location of >4 cm PTC. All patients underwent total thyroidectomy and bilateral CCND with/without lateral neck dissection. All patients underwent high-resolution ultrasound and fine needle aspiration before surgery. This study was approved by the Medical Ethics Committee of Qilu Hospital of Shandong University (Project identification code: 2018149). All patients were communicated with written and oral information and patient consents to review their medical records were acquired. Patient data are not publicly available due to the sensitive nature of the information but are available from the corresponding author on reasonable request. This study was registered in the Research Registry (UIN: researchregistry5292). The study design is shown in the flowchart (Figure 1).

The following exclusion criteria were adopted: history of thyroidectomy, bilateral PTC proven by postoperative histology, tumor located within the isthmus or pyramidal lobe, and distant metastasis. Multifocal unilateral PTC was allowed. The patients were divided into two groups based on the status of bilateral CLNM. This study complies with the Declaration of Helsinki.

**Surgical Procedure**

All surgeries were performed by the same two experienced thyroid surgeons. The standardized CCND was as follows:
the demarcation of the prelaryngeal region was that the super-
ior border of the thyroid cartilage served as the super-
ior bound and the inferior border of the cricoid cartilage as
the inferior bound; the demarcation of the pretracheal
region was that the inferior border of the isthmus served
as the superior bound, the innominate artery served as the
inferior bound and the tangent of the lateral wall of the
trachea served as the lateral bound; and the demarcation of
the paratracheal region was that the common carotid artery
served as the lateral bound and the lateral wall of the
trachea served as the medial bound. Specimens from dif-
ferent regions were sent for histological examination.

Clinical Assessment
The following indicators were collected and analyzed:
age, gender, place of residence, education level, tumor
location, tumor size, multifocality, aggressive pathology,
intraglandular dissemination, extrathyroidal extension,
number of metastatic lymph nodes, lateral neck
LNM, underlying conditions of Hashimoto’s thyroidi-
tis, and BRAF V600E mutation. The primary tumor
location was subjectively categorized as the upper
lobe, middle lobe, lower lobe and near isthmus
(Figure 2A). A near-isthmus tumor was defined as a
tumor with the border exceeding the lateral wall of
the trachea (Figure 2B). Tumors occupying both the
middle and the lower thyroid lobes were included in
the lower thyroid tumor category. Tumors occupying
the entire thyroid lobe were excluded from the
analysis. Intraglandular dissemination meant that can-
cerous embolisms with heterotypic cells and psam-
moma bodies were found in the lymphatic vessels
surrounding a major carcinoma.21 Tall cell variant,
solid variant, columnar cell variant and hobnail variant
were included in aggressive pathology.

Statistical Analysis
Assuming a 10% loss due to follow-up, at least 496
patients were needed to achieve 90% power at a 5% sig-
nificance level on the basis of our practical experience
and the rate of bilateral CLNM described in previous
publications.10–14

Statistical analyses were performed using IBM
SPSS Statistics for Windows, version 21.0 (IBM
Corp., Armonk, N.Y., USA). We used descriptive sta-
tistics to summarize the demographics and clinico-
pathological characteristics. Continuous variables are
presented as the mean±standard deviation (SD) and
were compared using the t-test or Mann–Whitney
U-test. Conversely, categorical variables are presented
as frequencies (percentages) and were compared using
the chi-squared test or Fisher’s exact test. Before mul-
tivariate logistic regression analysis, a collinearity test
was conducted for variables that may influence the risk
of bilateral CLNM in univariate analysis. In the multi-
variate analysis, binomial logistic regression analysis
was performed to estimate the odds ratio (OR) and the
95% confidence interval (95% CI) of bilateral CLNM.
To further determine the roles of the risk factors for different age patients, we performed a subgroup analysis using the cutoff of 55 years of age of the eighth edition of the AJCC/TNM cancer staging system. One-way analysis of variance (ANOVA) was used to compare the effects of different tumor locations on tumor size and the number of metastatic lymph nodes. A p value < 0.05 was considered statistically significant, and the reported p values were two-sided.

**Results**

Of the 1827 initial PTC patients, 33 patients with tumors occupying the entire lobe were excluded, and 6 patients were lost to follow-up. Twenty-one patients were excluded due to bilateral PTC verified by postoperative histology. A total of 1767 patients were ultimately analyzed (Figure 1). The demographic, clinical and pathological characteristics of all patients are shown in Table 1. The mean patient age was 49.1 ±12.3 (range 23–73) years. The majority of patients were women (n=1334, 75.4%). The tumor size ranged from 11 to 40 mm (average 19.1±7.4 mm). The tumors were mostly distributed in the right lobes (n=1123, 63.6%) and less frequently in the left lobes (n=644, 36.4%). These tumors were located in the upper lobe in 190 (10.7%) patients, middle lobe in 793 (44.8%) patients, lower lobe in 638 (36.1%) patients, and near isthmus in 146 (8.2%) patients. There was ipsilateral paratracheal LNM in 851 (48.2%) patients and bilateral CLNM in 256 (14.5%) patients. Additionally, pretracheal and prelaryngeal LNM were found in 92 and 28 patients, respectively, and lateral neck LNM was found in 207 (11.7%) patients.

In the univariate analysis (Table 2), patients with bilateral CLNM had more ipsilateral paratracheal (p<0.001) and pretracheal (p=0.001) metastatic lymph nodes. In addition, being male (p<0.001), tumor size (p<0.001), aggressive pathology (p<0.001) and lateral neck LNM (p=0.002) were more likely to be associated with bilateral CLNM. Tumor location was significantly different between the positive and negative bilateral CLNM groups (p<0.001). Positive bilateral CLNM accounted for 10.5% (20/190) of the upper lobe tumors, 11.0% (87/793) of the middle lobe tumors, 13.5% (86/638) of the lower lobe tumors and 43.2% (63/146) of the near-isthmus tumors (Table 2).

The number of metastatic lymph nodes was removed from multivariate logistic regression analysis because of collinearity with other risk factors. In the final multivariate analysis, male sex (OR 3.833, 95% CI: 2.832–5.186, p<0.001), tumor size (OR 1.392, 95% CI: 1.011–1.916, p=0.043), aggressive pathology (OR 9.159, 95% CI: 5.717–14.673, p<0.001) and lateral neck LNM (OR

### Table 1 The Demographic and Clinicopathological Characteristics of the Patients

| Characteristic                 | Patients n=1767 (%) |
|-------------------------------|---------------------|
| Age (min-max)                 | 49.1±12.3 (23–73)   |
| Sex                           |                     |
| Male                          | 433 (24.5)          |
| Female                        | 1334 (75.4)         |
| Place of residence            |                     |
| City                          | 1123 (63.6)         |
| Village                       | 644 (36.4)          |
| Education level               |                     |
| Primary school or high school | 516 (29.2)          |
| College or university         | 1251 (70.8)         |
| Tumor size (mm)               | 19.1±7.4            |
| Aggressive pathology          | 97 (5.4)            |
| Multifocality                 | 256 (14.5)          |
| Intraglandular dissemination  | 47 (2.7)            |
| Extrathyroidal extension      | 931 (52.7)          |
| Tumor laterality              |                     |
| Right lobe                    | 1123 (63.6)         |
| Left lobe                     | 644 (36.4)          |
| Tumor location                |                     |
| Upper lobe                    | 190 (10.7)          |
| Middle lobe                   | 793 (44.8)          |
| Lower lobe                    | 638 (36.1)          |
| Near isthmus                  | 146 (8.2)           |
| CLNM (pN1a)                   |                     |
| Ipsilateral paratracheal LNM  | 851 (48.2)          |
| Bilateral CLNM                | 256 (14.5)          |
| Pretracheal LNM               | 92 (5.2)            |
| Prelaryngeal LNM              | 28 (1.6)            |
| Lateral neck LNM, n (%)       | 207 (11.7)          |
| Hashimoto’s thyroiditis       | 384 (21.7)          |
| BRAF mutation (+)             | 1306 (73.9)         |

**Abbreviations:** CLNM, central lymph node metastasis; LNM, lymph node metastasis.
2.266, 95% CI: 1.482–3.464, p<0.001) were independent predictive factors of bilateral CLNM (Table 3). Tumor location was also an independent predictive factor of bilateral CLNM after adjusting for the above risk factors.

Compared to upper lobe tumors, near-isthmus tumors continued to demonstrate the highest risk of bilateral CLNM in a multivariate regression model (OR 7.319, 95% CI: 3.844–13.933, p<0.001), followed by lower lobe tumors.

### Table 2 Clinical and Pathological Characteristics Related to Bilateral CLNM in Univariate Analysis

| Characteristics                        | Positive Bilateral CLNM n=256 | Negative Bilateral CLNM n=1511 | p value |
|----------------------------------------|-------------------------------|-------------------------------|---------|
| Age (min-max)                          | 50.1±11.3 (23–69)             | 48.9±12.5 (27–73)             | 0.135   |
| Gender                                 |                               |                               |         |
| Male, n (%)                            | 131 (29.6%)                   | 302 (70.4%)                   | <0.001* |
| Female, n (%)                          | 125 (9.4%)                    | 1209 (90.6%)                  |         |
| Place of residence                     |                               |                               | 0.001*  |
| City, n (%)                            | 151 (13.4%)                   | 972 (86.6%)                   |         |
| Village, n (%)                         | 105 (16.3%)                   | 539 (83.7%)                   |         |
| Education level                        |                               |                               | 0.169   |
| Primary or high school                 | 84 (16.3%)                    | 432 (83.7%)                   |         |
| College or university                  | 172 (13.7%)                   | 1079 (86.3%)                  |         |
| Tumor size (mm)                        | 20.9±7.9                      | 18.8±7.2                      | 0.001*  |
| Aggressive pathology, n (%)            | 56 (37.7%)                    | 41 (42.3%)                    | <0.001* |
| Multifocality, n (%)                   | 43 (16.8%)                    | 213 (83.2%)                   | 0.256   |
| Intraglandular dissemination, n (%)    | 5 (10.6%)                     | 42 (89.4%)                    | 0.447   |
| Extrathyroidal extension, n (%)        | 129 (13.9%)                   | 802 (86.1%)                   | 0.426   |
| Tumor laterality                       |                               |                               |         |
| Right lobe                             | 152 (13.5%)                   | 971 (86.5%)                   | 0.133   |
| Left lobe                              | 104 (16.1%)                   | 540 (83.9%)                   |         |
| Tumor location                         |                               |                               | <0.001* |
| Upper lobe                             | 20 (10.5%)                    | 170 (89.5%)                   |         |
| Middle lobe                            | 87 (11.0%)                    | 706 (89.0%)                   |         |
| Lower lobe                             | 86 (13.5%)                    | 552 (86.5%)                   |         |
| Near isthmus                           | 63 (43.2%)                    | 83 (56.8%)                    |         |
| Number of metastatic lymph nodes in ipsilateral paratracheal region | 6.9±1.5 | 2.0±2.7 | <0.001* |
| Number of metastatic lymph nodes in pretracheal region | 0.3±0.9 | 0.1±0.6 | 0.001* |
| Number of metastatic lymph nodes in prelaryngeal region | 0.1±0.4 | 0.03±0.3 | 0.114 |
| Total number of metastatic lymph nodes | 7.2±2.3 | 2.2±3.0 | <0.001* |
| Lateral neck LNM, n (%)                | 45 (21.7%)                    | 162 (78.3%)                   | 0.002*  |
| Hashimoto’s thyroiditis, n (%)         | 48 (12.5%)                    | 336 (87.5%)                   | 0.211   |
| BRAF mutation+, n (%)                  | 179 (13.7%)                   | 1127 (86.3%)                  | 0.116   |

**Note:** * p<0.05.

**Abbreviations:** CLNM, central lymph node metastasis; LNM, lymph node metastasis.
As shown in the subgroup analysis, near-isthmus tumors still had the highest risk of bilateral CLNM among patients in the <55 years group (OR 5.508, 95% CI: 2.371–12.793, p<0.001) and ≥55 years group (OR 10.811, 95% CI: 3.895–30.008, p<0.001) (Table 4). Male sex and aggressive pathology remained independent predictive factors of bilateral CLNM in both subgroups. Tumor size was an independent predictive factor of bilateral CLNM in patients <55 years but not in patients ≥55 years. However, lateral neck LNM was an independent predictive factor of bilateral CLNM in patients ≥55 years but not in patients <55 years.

Compared with near-isthmus tumors, the tumors located in the lower lobe (p=0.021) and middle lobe (p=0.003) were larger, but the tumors located in the upper lobe were smaller (p=0.008) (Figure 3). Additionally, near-isthmus tumors had more pretracheal metastatic lymph nodes than upper (p=0.001) and middle lobe tumors (p=0.027) but not lower lobe tumors (p=0.07) (Figure 4B). More ipsilateral paratracheal metastatic lymph nodes were found in lower lobe tumors than in upper lobe tumors (p=0.03) (Figure 4A). Both near isthmus and lower lobe tumors had more total metastatic lymph nodes than upper lobe tumors (p=0.027 and 0.008, respectively) (Figure 4D). However, the prelaryngeal metastatic lymph nodes of all tumor locations were not significantly different (Figure 4C).

### Discussion

This study shows that tumor location is an independent risk factor for bilateral CLNM in unilateral 1–4 cm PTC. While near-isthmus tumors were the least frequent (8.2%), they had the highest risk of bilateral CLNM. Furthermore, near-isthmus tumors were smaller and had more metastatic lymph nodes in the pretracheal region. Tumors located in the upper lobe were associated with the lowest risk of bilateral CLNM.

The risk factors for bilateral CLNM, such as male sex, tumor size, extrathyroidal extension, ipsilateral

### Table 3 Multivariate Logistic Regression Analysis for Bilateral CLNM in All Patients

| Variables       | OR    | 95% CI     | p   |
|-----------------|-------|------------|-----|
| Tumor location  |       |            |     |
| Upper lobe (reference) | –     | –          | –   |
| Middle lobe     | 1.845 | 1.035–3.291| 0.038|
| Lower lobe      | 2.338 | 1.315–4.155| 0.004|
| Near isthmus    | 7.319 | 3.844–13.933| 0.001|
| Tumor size      | 1.392 | 1.011–1.916| 0.043|
| Male            | 3.833 | 2.832–5.186| <0.001|
| Aggressive pathology | 9.159 | 5.717–14.673| <0.001|
| Lateral neck LNM| 2.266 | 1.482–3.464| <0.001|

**Abbreviations:** CLNM, central lymph node metastasis; LNM, lymph node metastasis.

### Table 4 Multivariate Logistic Regression Analysis for Bilateral CLNM Grouping Patients by Age

| Variables       | Age <55 Group | Age ≥55 Group |
|-----------------|---------------|---------------|
|                 | OR | 95% CI     | p   | OR | 95% CI     | p   |
| Tumor location  |       |            |     |     |            |     |
| Upper (reference) | – | –          | –   | – | –          | –   |
| Middle lobe     | 1.907 | 0.908–4.004 | 0.088 | 1.691 | 0.657–4.353 | 0.276|
| Lower lobe      | 1.881 | 0.888–3.987 | 0.099 | 3.065 | 1.223–7.682 | 0.017|
| Near isthmus    | 5.508 | 2.371–12.793| <0.001 | 10.811 | 3.895–30.008 | <0.001|
| Tumor size      | 1.666 | 1.105–2.513 | 0.015 | 1.081 | 0.640–1.824 | 0.771|
| Male            | 3.947 | 2.665–5.847 | <0.001 | 3.867 | 2.385–6.269 | <0.001|
| Aggressive pathology | 9.472 | 5.150–17.421| <0.001 | 8.146 | 3.790–17.504| <0.001|
| Lateral neck LNM| 1.738 | 0.987–3.060 | 0.055 | 3.455 | 1.770–6.745 | <0.001|

**Abbreviations:** CLNM, central lymph node metastasis; LNM, lymph node metastasis.
CLNM, and lateral neck LNM, have been reported in some published literature. 

This study also confirmed that male sex, aggressive pathology, lateral neck LNM and tumor size were predictors of bilateral CLNM. However, extrathyroidal extension was not found to be an independent risk factor for bilateral CLNM. This is probably because most extrathyroidal extension was detected only by microscopy and had no impact on LNM. When tumor location was added to the above model with the adjustment of other known features, it was still an independent risk factor to predict bilateral CLNM. Some studies have reported that the risk of cervical LNM was associated with tumor location in PTC. 

However, there is no research regarding the effect of tumor location on the risk of bilateral CLNM. The aim of this study was to assess the effect of tumor location on the risk of bilateral CLNM. According to the results, near-isthmus tumors had the highest risk of bilateral CLNM and more metastatic lymph nodes in the pretracheal region. Therefore, the identification of tumor location and intraoperative frozen section examinations of lymph nodes in the pretracheal region may be useful in determining the appropriate extent of CCND. Some studies have reported that intraoperative frozen section examinations of ipsilateral lymph nodes have high sensitivity, specificity and accuracy in predicting contralateral nodal status. 

However, one limitation of this study was the retrospective nature, which induced the risk of selection bias. The other limitation was that BRAF gene mutation is not the only genetic factor that may impact LNM. Further studies on the molecular mechanism of LNM are necessary. Additionally, long-term postoperative follow-up data are also needed.

**Conclusion**

In summary, our data indicate that tumor location may be an independent factor for the risk of bilateral CLNM in unilateral 1–4 cm PTC. Near-isthmus tumors have the highest risk of bilateral CLNM while tumors in the upper lobe have the lowest risk. Furthermore, thyroid tumors located in the near isthmus have more metastatic lymph nodes in the pretracheal region. These data may help to carefully evaluate near-isthmus tumors in thyroid surgery and determine the treatment plan for surveillance or the ultimate extent of CCND.
Figure 4 The number of metastatic lymph nodes in different tumor locations in ANOVA analyses. (A) Number of metastatic lymph nodes in the ipsilateral paratracheal region. (B) Number of metastatic lymph nodes in the pretracheal region. (C) Number of metastatic lymph nodes in the prelaryngeal region. (D) Total number of metastatic lymph nodes in three regions. * p<0.05 and ** p<0.01.

Abbreviations
PTC, papillary thyroid carcinoma; LNM, lymph node metastasis; CLNM, central lymph node metastasis; CCND, central compartment neck dissection.

Acknowledgments
This research was supported by the Key Technology Research and Development Program of Shandong Province (grant No. 2019GSF108072).
Disclosure
The authors have no conflicts of interest to declare that they are relevant to the content of this article.

References

1. Uedelsman R, Zhang Y. The epidemic of thyroid cancer in the United States: the role of endocrinologists and ultrasound. Thyroid. 2014;24(3):472–479. doi:10.1089/thy.2013.0257
2. La Vecchia C, Malvezzi M, Bosetti C, et al. Thyroid cancer mortality and incidence: a global overview. Int J Cancer. 2015;136(9):2187–2195. doi:10.1002/jic.28251
3. Haugen BR, Alexander EK, Bible KC, et al. American Thyroid Association Management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133. doi:10.1089/thy.2015.0020
4. Kouvaraki MA, Shapiro SE, Fornage BD, et al. Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery. 2003;134(6):946–954; discussion 954–955. doi:10.1016/s0039-6606(03)00424-0
5. Hughes DT, White ML, Miller BS, Gauger PG, Burney RE, Doherty GM. Influence of prophylactic central lymph node dissection on postoperative thyroglobulin levels and iodineoid treatment in papillary thyroid cancer. Surgery. 2010;148(6):1100–1106; discussion 1006–1007. doi:10.1016/j.surg.2010.09.019
6. Randolph GW, Duh Q-Y, Heller KS, et al. The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. Thyroid. 2012;22(11):1144–1152. doi:10.1089/thy.2012.0043
7. Lee KE, Chung IY, Kang E, et al. Ipsilateral and contralateral central lymph node metastasis in papillary thyroid cancer: patterns and predictive factors of nodal metastasis. Head Neck. 2013;35(5):672–676. doi:10.1002/hed.23016
8. Eun YG, Lee YC, Kwon KH. Predictive factors of contralateral paraaortic lymph node metastasis in papillary thyroid cancer: prospective multicenter study. Otolaryngol Head Neck Surg. 2014;150(2):210–215. doi:10.1177/0194599813514726
9. Delogu D, Pisano IP, Pala C, et al. Prophylactic central neck lymphadenectomy in high risk patients with T1 or T2 papillary thyroid carcinoma: is it useful? Ann Ital Chir. 2014;85(3):225–229.
10. Zhou B, Qin J. High-risk factors for lymph node metastasis in contralateral central compartment in unilateral papillary thyroid carcinoma (cTN1b). Eur J Surg Oncol. 2021;47(7):882–887. doi:10.1016/j.ejso.2020.10.018
11. Hei H, Song Y, Qin J. A nomogram predicting contralateral central neck lymph node metastasis for papillary thyroid carcinoma. J Surg Oncol. 2016;114(6):703–707. doi:10.1002/jso.24403
12. Wei T, Chen R, Zou X, Liu F, Li Z, Zhu J. Predictive factors of contralateral paratracheal lymph node metastasis in unilateral papillary thyroid carcinoma. Eur J Surg Oncol. 2015;41(6):746–750. doi:10.1016/j.ejso.2015.02.013
13. Chen Q, Wei T, Wang X-L, Li Z-H, Du Z-H, Zhu J-Q. The total number of prelaryngeal and pretracheal lymph node metastases: is it a reliable predictor of contralateral central lymph node metastasis in papillary thyroid carcinoma? J Surg Res. 2017;214:162–167. doi:10.1016/j.jss.2017.05.056
14. Zhou L, Li H, Liang W, Gao C, Chen B. Pretracheal-laryngeal lymph nodes in frozen section predicting contralateral paratracheal lymph nodes metastasis. Eur J Surg Oncol. 2020;46(10 Pt A):1829–1834. doi:10.1016/j.ejso.2020.06.048
15. Podnos YD, Smith D, Wagman LD, Ellenhorn JDI. The implication of lymph node metastasis on survival in patients with well-differentiated thyroid cancer. Am Surg. 2005;71(9):731–734. doi:10.1177/000313480507100907
16. Lebouleux S, Rubino C, Baudin E, et al. Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. J Clin Endocrinol Metab. 2005;90(10):5723–5729. doi:10.1210/jc.2005-0285
17. Sugitani I, Kasai N, Fujimoto Y, Yanagisawa A. A novel classification system for patients with PTc: addition of the new variables of large (3 cm or greater) nodal metastases and reclassification during the follow-up period. Surgery. 2004;135(2):139–148. doi:10.1016/s0039-6060(03)00384-2
18. Adam MA, Pura J, Goffredo P, et al. Presence and number of lymph node metastases are associated with compromised survival for patients younger than age 45 years with papillary thyroid cancer. J Clin Oncol. 2015;33(21):2370–2375. doi:10.1200/JCO.2014.59.8391
19. Roh J-L, Kim J-M, Park CI. Central lymph node metastasis of unilateral papillary thyroid carcinoma: patterns and factors predictive of nodal metastasis, morbidity, and recurrence. Ann Surg Oncol. 2011;18(8):2245–2250. doi:10.1245/s10434-011-1600-2
20. Miao S, Mao X, Pei R, et al. Predictive factors for different subgroups of central lymph node metastasis in unilateral papillary thyroid carcinoma. ORL J Otorhinolaryngol Relat Spec. 2013;75(5):265–273. doi:10.1007/s00054-2013-0278-8
21. Jin H, Yan H, Tang H, Zheng M, Wu C, Liu J. Internal spreading of papillary thyroid carcinoma: a case report and systemic review. Case Rep Endocrinol. 2018;2018:7618456. doi:10.1155/2018/7618456.
22. Tuttle M, Morris LF, Haugen B, et al. Thyroid-differentiated and anaplastic carcinoma. In: Amin MB, Edge SB, Greene F, et al., editors. AJCC Cancer Staging Manual. 8th ed. New York: Springer International Publishing; 2017:873–891.
23. Sancaktar ME, Saylam G, Öcal B, et al. Possible prediction of patterns of cervical lymph node spread based on primary tumor location in papillary thyroid carcinomas. Turk J Med Sci. 2019;49 (1):217–221. doi:10.3906/sag-1807-79
24. Back K, Kim JS, Kim J-H, Choe J-H. Superior located papillary thyroid microcarcinoma is a risk factor for lateral lymph node metastasis. Ann Surg Oncol. 2019;26(12):3992–4001. doi:10.1245/s10434-019-07587-2
25. Lee YS, Shin S-C, Lim Y-S, et al. Tumor location-dependent skip lateral cervical lymph node metastasis in papillary thyroid carcinoma. Singap Med J. 2016;57(9):e244–e248. doi:10.11622/smj.2016.57.9.e244
26. Lee YS, Jeong JJ, Nam K-H, Chung WY, Chang H-S, Park CS. Papillary carcinoma located in the thyroid isthmus: a case control study. Eur J Surg Oncol. 2014;40(8):1479–1484. doi:10.1016/j.ejso.2014.05.008
27. Karatzas T, Charitoudis G, Vasileiadis D, Kapetanakis S, Vasileiadis I. Surgical treatment for dominant malignant nodules of the isthmus of the thyroid gland: a case control study. Int J Surg. 2015;18:64–68. doi:10.1016/j.ijsu.2015.04.039
28. Lee YS, Jeong JJ, Nam K-H, Chung WY, Chang H-S, Park CS. Papillary carcinoma located in the thyroid isthmus. World J Surg. 2010;34(1):36–39. doi:10.1007/s00268-009-0298-6
29. Mai KT, Gulavita P, Lai C, et al. Topographic distribution of papillary thyroid carcinoma by mapping in coronal sections of 125 consecutive thyroidectomy specimens. Int J Surg Pathol. 2014;22(4):303–315. doi:10.1177/1068167X13503491
30. Nixon JJ, Palmer FL, Whitcher MM, et al. Thyroid ishmusectomy for well-differentiated thyroid cancer. Ann Surg Oncol. 2011;18(3):767–770. doi:10.1245/s10434-010-1358-8
32. Vasileiadis I, Boutzios G, Karalaki M, Misiakos E, Karatzas T. Papillary thyroid carcinoma of the isthmus: total thyroidectomy or isthmusectomy? *Am J Surg*. 2018;216(1):135–139. doi:10.1016/j.amjsurg.2017.09.008

33. Song CM, Lee DW, Ji YB, Jeong JH, Park JH, Tae K. Frequency and pattern of central lymph node metastasis in papillary carcinoma of the thyroid isthmus. *Head Neck*. 2016;38(Suppl 1):E412–416. doi:10.1002/hed.24009

34. Hahn SY, Han B-K, Ko EY, Shin JH, Ko ES. Ultrasound findings of papillary thyroid carcinoma originating in the isthmus: comparison with lobe-originating papillary thyroid carcinoma. *AJR Am J Roentgenol*. 2014;203(3):637–642. doi:10.2214/AJR.13.10746

35. Chai YJ, Kim S-J, Choi JY, Koo DH, Lee KE, Youn Y-K. Papillary thyroid carcinoma located in the isthmus or upper third is associated with Delphian lymph node metastasis. *World J Surg*. 2014;38(6):1306–1311. doi:10.1007/s00268-013-2406-x

36. Lee YC, Na SY, Chung H, Kim SI, Eun Y-G. Clinicopathologic characteristics and pattern of central lymph node metastasis in papillary thyroid cancer located in the isthmus. *Laryngoscope*. 2016;126(10):2419–2421. doi:10.1002/lary.25926

37. Santrae N, Besic N, Buta M, et al. Lymphatic drainage, regional metastases and surgical management of papillary thyroid carcinoma arising in pyramidal lobe—a single institution experience. *Endocr J*. 2014;61(1):55–59. doi:10.1507/endocrj.ej13-0316

38. Lee DH, Yoon TM, Kim HK, Lee JK, Kang HC, Lim SC. Intraoperative frozen biopsy of central lymph node in the management of papillary thyroid microcarcinoma. *Indian J Otolaryngol Head Neck Surg*. 2016;68(1):56–59. doi:10.1007/s12070-015-0900-1

39. Raffaelli M, De Crea C, Sessa L, Giustacchini P, Bellantone R, Lombardi CP. Can intraoperative frozen section influence the extension of central neck dissection in cN0 papillary thyroid carcinoma? *Langenbecks Arch Surg*. 2013;398(3):383–388. doi:10.1007/s00423-012-1036-3

40. Raffaelli M, De Crea C, Sessa L, Fadda G, Bellantone C, Lombardi CP. Ipsilateral central neck dissection plus frozen section examination versus prophylactic bilateral central neck dissection in cN0 papillary thyroid carcinoma. *Ann Surg Oncol*. 2015;22(7):2302–2308. doi:10.1245/s10434-015-4383-9